Why the study?
Treatment-dose enoxaparin is not well studied in obese patients, and standard actual body weight dosing may be overestimated, potentially increasing bleeding risk.
Does treatment-dose enoxaparin at 1 mg/kg increase bleeding risk or supratherapeutic anti-Xa levels in patients with BMI ≥ 40 kg/m2?
Population
102 patients with BMI ≥ 40 kg/m 2 ordered treatment-dose enoxaparin
Design
Single-center retrospective chart review
Authors
Loading...
May warrant anti-Xa monitoring or dose adjustment in obese VTE patients; leaves open optimal regimen pending prospective trials.
Does treatment-dose enoxaparin at 1 mg/kg increase bleeding risk or supratherapeutic anti-Xa levels in patients with BMI ≥ 40 kg/m2?
Berger et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: